The live-attenuated yellow fever 17D (YF17D) vaccine was employed as a vector to express the profusion form of the SARS-CoV-2 Spike antigen. The vaccine candidate, tentatively named YF-S0, induces high levels of SARS-CoV-2 neutralizing antibodies and a favorable Th1 cell-mediated immune response in mice. In a stringent hamster SARS-CoV-2 challenge model, vaccine candidate YF-S0 prevents infection with SARS-CoV-2. Moreover, a single dose confers protection from lung disease in most vaccinated animals even within 10 days. These results warrant further development of YF-S0 as a potent SARS-CoV-2 vaccine candidate.  

A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate

- Codagenix Incorporation’s proprietary deoptimized SARS-CoV-2 vaccine candidate (most prominent)
- A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate

Smith College

Syracuse University

Live-attenuated vaccines (LAVs) are live, reproducing, yet mild viruses. The designs are meant to produce single-dose immunity without illness. 


Live-attenuated vaccines

Shin, M.D., Shukla, S., Chung, Y.H. et al. COVID-19 vaccine development and a potential nanomaterial path forward. Nat. Nanotechnol. 15, 646–655 (2020). doi: 10.1038/s41565-020-0737-y

https://doi.org/10.1038/s41565-020-0737-y

COVID-19 vaccine development and a potential
nanomaterial path forward

- cold chain
- risk of viral transmission
- risk of reversion to pathogenic form
- reactivation in immunocompromised individuals
- recombination with related viruses circulating in the population
-people with suppressed immune systems majority of the time cannot get live vaccines

Learn Before

Related

Learn After